Met butne Reports Results of Two Phase 3 CAPACITY studies Pirfenidone In IPFInterMune are the results from the two Phase 3 CAPACITY studies in patients with idiopathic pulmonary fibrosis , pirfenidone.The primary endpoint of change in % predicted forced vital capacity at week 72 was with statistical significance in CAPACITY 2 , along with the secondary endpoints of categorical change in FVC and progression-free survival . The primary endpoint was not in CAPACITY 1 met, but supportive evidence of a pirfenidone treatment effect was observed a number of actions. Pirfenidone was safe and generally well tolerated in both CAPACITY studies was well tolerated.

The agreement involved the acquisition of patents and the elimination of all future royalties due to Marnac in exchange for a total advance payments of 13.5 million euros. Conditional acquisition of up to an additional $ 53,000 would be made InterMune only upon successful fulfillment of certain clinical development and regulatory milestones. InterMune provided additional details of this agreement in its press release dated 26 November 2007..Small cell lung is less frequent as non-small cell lung cancer. Around 15 to 20 %age of all lung cancers are the small cell type. This cancer usually begins in the bronchial tubes near to the center of the chest but have spreading spread outside of the lungs through the the time of diagnosis. Small cell lung cancer highly associated with a history of smoking.. On Small Cell Lung CancerThe National Cancer Institute estimates that 174,470 people with lung cancer in the USA have diagnose in 2006, and about 160,000 people every year from this disease.

Other articles from category "gastroenterology":

Random articles